despit
high
frequenc
pneumovir
infect
year
research
field
licens
vaccin
hmpv
rsv
current
avail
among
numer
vaccin
candid
rsv
develop
advanc
clinic
trial
fail
result
insuffici
immunogen
underattenu
antihmpv
vaccin
advanc
clinic
trial
liveattenu
recombin
rhmpvpa
viru
hmpvp
protein
exchang
counterpart
insuffici
immunogen
overattenu
seroneg
children
thu
leav
advanc
candid
antihmpv
vaccin
lack
effect
vaccin
candid
hmpv
explain
recent
discoveri
viru
also
lack
success
vaccin
close
relat
rsv
could
serv
base
vaccin
design
one
reason
slow
progress
field
clinic
failur
formalininactiv
rsvvaccin
firsv
occur
administr
firsv
led
develop
exagger
immun
respons
wild
type
wt
rsv
infect
enhanc
pulmonari
diseas
epd
two
vaccin
children
die
epd
document
variou
anim
model
indic
human
phenomenon
similar
effect
observ
formalin
heatinactiv
hmpv
vaccin
induc
symptom
epd
rodent
anoth
reason
slow
vaccin
develop
transient
immun
provid
natur
infect
rsv
hmpv
document
rsvseroposit
adult
level
rsvneutral
antibodi
correl
resist
subsequ
rsv
infect
protect
confer
incomplet
shortlast
result
frequent
reinfect
immun
respons
primari
hmpv
infect
describ
weak
aberr
balbc
mice
excess
product
later
stage
infect
correl
airway
hyperrespons
develop
asthma
pneumovirus
also
develop
mani
mechan
evad
immun
respons
rsv
nonstructur
protein
suppress
ifninduc
antivir
respons
infect
cell
remov
protein
result
induct
high
level
ifn
alpha
beta
vitro
hmpv
share
rsv
abil
decreas
ifn
respons
despit
lack
protein
document
hmpvg
protein
abil
inhibit
ifn
type
respons
vitro
vivo
sh
protein
also
modul
host
immun
respons
hmpv
rsv
persist
lung
infect
anim
host
despit
presenc
neutral
antibodi
persist
document
rtpcr
detect
viral
rna
guinea
pig
mous
model
rsv
mice
hmpv
anoth
hurdl
effect
immun
presenc
matern
antibodi
bloodstream
vaccin
infant
impair
immunogen
effect
vaccin
yet
role
matern
antibodi
rsv
infect
fulli
understood
main
object
pneumoviru
vaccin
develop
avoid
epd
obtain
suffici
immunogen
without
caus
diseas
viral
protein
antigen
use
subunit
vaccin
induc
appropri
immun
respons
protein
deliv
nanoparticl
viruslik
particl
vlp
coupl
adjuv
anoth
interest
strategi
immun
viral
nucleic
acid
code
viral
antigen
document
rsv
hmpv
vaccin
candid
mrnabas
vaccin
code
f
protein
hmpv
human
parainfluenza
type
viru
recent
advanc
phase
clinic
trial
among
three
surfac
protein
hmpv
f
g
sh
f
protein
constitut
major
hmpv
antigen
although
immunogen
g
protein
induc
potent
protect
immun
respons
indispens
viral
replic
vivo
hmpvsh
protein
shown
confer
signific
protect
observ
rsv
f
protein
also
major
antigen
rsv
immunogen
g
protein
although
latter
also
abl
induc
protect
immun
respons
frequent
test
subunit
vaccin
rsvf
protein
stabil
prefus
form
introduc
disulfid
bond
ds
cavityfil
mutat
current
test
subunit
vaccin
phase
clinic
trial
clinicaltrialsgov
identifi
prefus
rsvf
shown
immunogen
postfus
conform
result
exposit
uniqu
antigen
site
recogn
potent
rsvneutral
antibodi
trial
hmpvf
subunit
vaccin
show
vaccin
immunogen
protect
rodent
model
increas
immunogen
potenti
hmpvf
protein
stabil
prefus
state
analog
strategi
rsvf
immunogen
enhanc
differ
prefus
rsvf
hmpvf
explain
addit
glycosyl
apex
prefus
form
hmpvf
hmpvf
rsvf
share
antigen
site
antibodi
abl
crossneutr
two
pneumovirus
identifi
graft
major
protect
epitop
rsvf
hmpvf
protein
result
elabor
chimer
protein
carri
epitop
pneumovirus
interest
candid
vaccin
design
sever
promis
nanoparticl
vaccin
rsv
elabor
among
resvax
nanoparticl
rsvfbase
vaccin
develop
novavax
resvax
recent
test
phase
clinic
trial
matern
immun
model
lower
rti
prevent
infant
meet
clinic
endpoint
vlp
structur
compos
protein
viral
capsid
contain
viral
genom
replicationincompet
coexpress
hmpvf
g
protein
lead
format
vlp
vitro
yet
express
f
protein
shown
suffici
vlp
assembl
sever
potenti
vlp
vaccin
hmpv
mani
rsv
develop
none
advanc
clinic
trial
promis
vaccin
vlp
compos
prefus
postfus
rsvf
togeth
assembl
hmpvm
full
protect
rsv
infect
immun
mice
hand
immun
attenu
replicationcompet
viru
promis
approach
case
possibl
obtain
vaccin
present
viral
epitop
abl
induc
humor
cellular
immun
respons
main
disadvantag
live
attenu
vaccin
risk
revers
attenu
profil
restor
infect
subsequ
develop
diseas
live
attenu
virus
divid
two
group
nonrecombin
recombin
chimer
virus
nonrecombin
virus
render
less
infecti
due
genet
modif
appear
natur
serial
passag
vitro
condit
environment
stress
sever
attenu
strain
rsv
hmpv
obtain
result
serial
cold
passag
chemic
mutagenesi
confer
temperaturesensit
ts
phenotyp
viru
apart
mention
select
strategi
recombin
attenu
virus
gener
revers
genet
techniqu
make
possibl
gener
function
particl
modifi
viru
base
genet
materi
approach
allow
introduc
attenu
mutat
directli
viral
genom
also
express
exogen
antigen
backbon
viru
lead
develop
polyval
chimer
vaccin
insert
foreign
gene
potenti
attenu
effect
exampl
rearrang
order
gene
term
express
gradient
observ
paramyxovirus
gene
order
also
chang
invas
way
move
virul
gene
highexpress
posit
lowexpress
locu
altern
replic
effici
decreas
delet
silenc
nonessenti
viral
protein
play
accessori
function
life
cycl
viru
also
possibl
swap
gene
strain
differ
host
prefer
thu
introduc
new
host
rang
restrict
hmpv
viru
p
gene
exchang
ampvc
counterpart
rhmpvpa
attenu
wt
hmpv
yet
protect
hmpv
infect
african
green
monkey
agm
review
focu
discuss
detail
develop
live
recombin
vaccin
hmpv
ultim
goal
hmpv
vaccin
prevent
lower
rti
popul
risk
similarli
rsv
target
popul
hmpv
vaccin
young
children
elderli
peopl
pregnant
women
earli
vaccin
infant
young
children
potenti
prevent
hmpvinfect
transmiss
viru
replicationcompet
vaccin
name
liveattenu
hmpv
recombin
virus
good
choic
popul
anoth
vaccin
strategi
primeboost
regimen
consist
vaccin
genebasedl
vaccin
first
proteinparticlebas
vaccin
immun
pregnant
women
provid
passiv
antibodi
transfer
children
also
prevent
mothertochild
transmiss
hmpv
live
vaccin
consid
riski
use
popul
therefor
subunit
vaccin
vlp
standard
adjuv
consid
effect
vaccin
adult
popul
live
vaccin
hamper
presenc
antihmpv
antibodi
bloodstream
respiratori
tract
rt
vaccin
elderli
peopl
experienc
multipl
hmpv
infect
subunit
vlp
potent
adjuv
recommend
one
strategi
aim
circumv
problem
incomplet
immun
provid
natur
hmpv
infect
express
protect
antigen
backbon
immunogen
viru
increas
immunogen
also
provid
improv
antigen
express
vector
demonstr
recombin
bovinehuman
express
either
rsvf
g
protein
human
parainfluenza
type
viru
express
hmpv
antigen
hmpv
difficult
grow
cell
cultur
vector
antigen
backbon
betterrepl
viru
facilit
vaccin
develop
manufactur
instanc
express
rsvf
reach
higher
viral
titer
vivo
compar
wt
rsv
replic
effici
rt
agm
wt
rsv
hmpv
express
foreign
antigen
backbon
anoth
viru
also
mitig
problem
preexist
immun
often
diminish
effect
vaccin
use
vector
anoth
host
rang
facilit
immun
seroposit
individu
risk
caus
diseas
describ
newcastl
diseas
viru
ndv
express
rsvf
major
live
vaccin
rsv
hmpv
date
attenu
codon
chang
genom
therefor
use
stabli
attenu
backbon
render
attenu
reliabl
decreas
risk
revers
attenu
phenotyp
insert
addit
gene
influenc
viru
replic
capac
thu
limit
abil
spread
caus
diseas
also
creat
risk
overattenu
subtl
balanc
attenu
immunogen
remain
major
challeng
vaccin
develop
gener
vectorbas
chimer
vaccin
retain
advantag
live
attenu
vaccin
readili
gener
revers
genet
backbon
use
far
vector
pneumovir
antigen
belong
paramyxovirida
famili
virus
close
relat
phylogenet
structur
pneumovirus
close
relationship
increas
chanc
effici
express
integr
pneumovir
protein
background
paramyxovir
vector
among
paramyxovirus
wide
use
vaccin
backbon
bovin
parainfluenza
viru
type
recombin
deriv
parainfluenza
viru
type
newcastl
diseas
viru
ndv
sendai
viru
sev
reason
explain
frequent
use
paramyxovirus
vaccin
backbon
numer
first
genom
wellcharacter
complet
genom
sequenc
known
member
famili
easili
access
second
genom
simpl
organ
modular
way
tandem
align
gene
transcrib
separ
mrna
product
facilit
genet
manipul
third
paramyxovirus
abl
replic
effici
cell
line
certifi
vaccin
manufactur
vero
cell
facilit
vaccin
develop
fourth
replic
entir
cytoplasm
replic
cycl
involv
integr
host
cell
genom
use
potenti
safe
also
recombin
event
mononegavirus
observ
natur
remain
extrem
rare
vitro
even
optim
condit
indic
low
probabl
gene
exchang
engin
vaccin
virus
pathogen
present
environ
fifth
small
probabl
recombin
also
contribut
stabil
genet
insert
provid
stabl
foreign
gene
express
system
paramyxovirus
abl
stabli
express
sever
exogen
simultan
level
express
manipul
chang
posit
gene
insert
sixth
paramyxovirus
infect
host
via
rt
repres
easi
safe
rout
administr
vaccin
well
induct
local
system
immun
respons
last
least
mani
anim
paramyxovirus
natur
attenu
human
due
host
rang
restrict
mutat
render
virus
harmless
peopl
identifi
character
thu
make
attenu
differ
paramyxovirus
possibl
neg
strand
virus
readili
recov
cell
cultur
mean
revers
genet
techniqu
make
possibl
engin
fulli
function
viru
start
genet
sequenc
genet
materi
form
cdna
easili
modifi
accord
vaccin
design
techniqu
base
transfect
permiss
cell
plasmid
code
viral
genom
satellit
plasmid
code
protein
necessari
format
ribonucleoprotein
complex
rnp
initi
transcript
viral
gene
figur
protein
indispens
form
rnp
paramyxovirus
pneumovirus
n
p
l
protein
yet
addit
protein
facilit
recoveri
hmpv
cdna
elabor
polyval
vaccin
accomplish
either
clone
addit
gene
plasmid
code
viral
genom
replac
protect
antigen
vector
one
anoth
pathogen
genom
paramyxovirida
pneumovirida
consist
simpl
nonseg
linear
singlestrand
neg
rna
contain
gene
proxim
region
consist
leader
le
gene
preced
follow
short
nucleotid
conserv
sequenc
name
gene
start
gs
gene
end
ge
sequenc
act
like
transcript
control
signal
viral
rnadepend
rnapolymeras
vrnap
guid
enzym
along
genom
singl
gene
separ
short
noncod
intergen
region
order
gene
usual
conserv
nucleoprotein
n
phosphoprotein
p
matrix
protein
glycoprotein
g
hemagglutininneuraminidas
hn
larg
polymeras
subunit
l
presenc
locat
addit
gene
depend
viru
figur
end
genom
contain
trailer
sequenc
tr
variabl
length
rang
nucleotid
genom
rna
paramyxovirus
pneumovirus
exist
unbound
rnaparticl
alway
assembl
numer
copi
n
protein
form
helicoid
nucleocapsid
paramyxovirus
n
protein
molecul
associ
precis
six
nucleotid
featur
believ
underlay
rule
six
ie
length
genom
paramyxovirus
multipl
six
effect
viral
replic
stringent
adhes
rule
observ
sev
virus
like
ndv
strongli
increas
efficaci
replic
fact
give
replic
advantag
rsv
might
explain
distinct
differ
nucleocapsid
structur
two
famili
transcript
viral
genom
initi
end
express
gradient
observ
complex
vrnap
sporad
fail
resum
synthesi
anoth
distinct
mrna
gene
junction
result
gradual
loss
transcriptionefficaci
along
genom
main
principl
taken
consider
engin
genom
recombin
paramyxovirus
preferenti
adher
rule
six
coher
transcript
control
signal
gsge
use
drive
express
foreign
antigen
exogen
posit
transcript
gradient
document
numer
studi
gs
ge
signal
vector
viru
effici
direct
express
exogen
protein
although
gs
ge
signal
often
highli
conserv
along
viral
genom
might
variat
sequenc
transcript
efficaci
flank
sequenc
gfp
insert
genom
posit
gsge
specif
either
gene
junction
result
larg
differ
gfp
express
level
figur
gsge
characterist
junction
provid
better
express
level
one
origin
therefor
import
flank
exogen
potent
transcript
regul
accord
transcript
gradient
exogen
place
proxim
posit
express
better
proxim
insert
yet
tendenc
describ
linear
deviat
observ
adher
gradient
might
also
influenc
type
attenu
vector
viru
demonstr
bear
rsvf
protein
posit
exogen
viral
genom
describ
figur
nomenclatur
use
label
chimer
virus
review
explain
figur
one
hand
proxim
insert
provid
best
level
express
hand
influenc
level
transcript
downstream
gene
lead
decreas
viral
replic
rsvf
insert
posit
genom
reduc
express
downstream
gene
genom
posit
provid
good
express
also
influenc
n
p
protein
ratio
play
decis
role
replic
capac
paramyxovirus
caus
addit
attenu
effect
insert
either
genom
posit
privileg
vector
posit
usual
provid
better
viru
recoveri
higher
viral
replic
better
exogen
express
vector
name
ndv
avian
paramyxoviru
serotyp
posit
advantag
wherea
insert
one
result
delay
viral
replic
largest
reduct
viru
recoveri
posit
frequent
use
influenc
express
vector
surfac
protein
f
hn
except
studi
sev
bear
either
rsvf
hmpvf
posit
natur
insert
also
influenc
vector
biolog
viru
show
reduc
replic
vitro
compar
wherea
insert
influenc
viral
replic
decreas
viral
growth
might
due
excess
syncytia
format
increas
cytopatholog
result
express
second
fusion
protein
anoth
reason
might
size
bigger
f
protein
might
influenc
replic
significantli
smaller
g
protein
size
exogen
significantli
chang
replic
capac
viru
shown
vector
bear
insert
differ
size
level
integr
foreign
protein
vector
particl
also
price
pay
exchang
effici
express
exogen
describ
chapter
review
improv
exogen
integr
vector
backbon
obtain
substitut
transmembran
domain
tm
cytoplasm
tail
ct
insert
equival
vector
viru
demonstr
vector
bear
rsvf
protein
either
wt
chimer
tmct
form
packag
rsvf
tmct
strongli
improv
chimer
viru
overattenu
protect
hamster
replac
f
hn
gene
counterpart
result
elabor
recombin
viru
broadli
use
express
foreign
antigen
viru
immunogen
human
retain
attenu
profil
safeti
immunogen
document
adult
children
reach
higher
titer
vivo
rsv
make
good
platform
studi
antipneumovir
vaccin
genom
approxim
kb
length
includ
six
structur
gene
adher
rule
six
sever
virus
recov
genom
cdna
whose
length
fulfil
condit
found
accommod
nucleotid
insert
correct
genom
length
broadli
use
express
rsv
hmpv
antigen
exampl
vaccin
test
preclin
trial
shown
tabl
mani
differ
posit
test
rsvf
insert
gradual
decreas
exogen
express
observ
one
although
time
attenu
posit
one
provid
attract
attenuationexogen
express
ratio
viru
bear
rsvf
posit
develop
medimmun
test
phase
clinic
trial
proven
insuffici
immunogen
accommod
insert
rsvf
g
protein
posit
littl
decreas
replic
vitro
doubl
insert
place
posit
result
ts
phenotyp
restrict
replic
vivo
yet
viru
immunogen
protect
hamster
insert
hmpvf
gene
either
posit
genom
result
effici
exogen
express
integr
membran
protein
chimera
difficult
recov
replic
less
effici
observ
rsvf
insert
virus
immunogen
protect
hamster
viru
subsequ
evalu
vaccin
african
green
monkey
agm
viru
replic
better
wt
hmpv
protect
wt
hmpv
challeng
induc
effect
antihmpvspecif
tcell
respons
slightli
lower
compar
wt
hmpv
level
antibodi
induc
chimer
viru
correl
provid
protect
lower
respiratori
tract
lrt
infect
primat
infant
human
parainfluenza
type
major
caus
croup
respons
approxim
hpiv
infect
children
age
import
pediatr
pathogen
protect
vaccin
avail
use
viru
backbon
bival
vaccin
highli
warrant
share
genom
organ
hpiv
virus
recombin
test
vaccin
preclin
studi
agm
attenu
mutat
pc
hn
l
gene
test
vaccin
children
shown
welltoler
overattenu
consid
addit
attenu
effect
exogen
insert
subsequ
studi
concentr
bear
singl
attenu
exampl
base
vaccin
shown
tabl
mackow
et
al
test
vector
express
rsvf
genom
posit
show
backbon
overattenu
upon
rsvf
insert
backbon
suitabl
vector
subsequ
test
express
either
nativ
rsvf
chimer
rsvf
tmct
protein
posit
wild
type
test
vector
express
f
g
sh
surfac
protein
hmpv
examin
rel
contribut
induc
hmpvspecif
antibodi
contrari
insert
insert
impair
viru
growth
express
vector
hn
gene
vaccin
provid
signific
protect
wt
hmpv
challeng
even
two
dose
less
protect
singl
immun
wt
hmpv
studi
show
hmpvf
major
viral
antigen
immunogen
hmpvg
sh
backbon
also
use
express
f
protein
hmpva
evalu
abil
induc
crossprotect
hmpvb
studi
show
f
protein
hmpva
induc
crossprotect
heterolog
hmpv
strain
backbon
suitabl
vector
hmpv
antigen
sendai
viru
sev
murin
parainfluenza
type
viru
natur
host
rang
restrict
provid
safeti
human
risk
revers
attenu
phenotyp
capabl
induc
durabl
strong
immun
respons
sev
close
relat
develop
heterolog
vaccin
increas
protect
infect
anim
model
human
length
sev
genom
approxim
kb
viru
strictli
adher
rule
six
effici
replic
sev
shown
accommod
stabli
express
insert
kb
size
replic
rate
invers
correl
total
genom
length
broadli
use
backbon
express
rsvf
g
protein
genom
posit
test
vaccin
alon
formul
multipl
recombin
sev
express
antigen
differ
hpiv
type
genom
posit
also
use
express
hmpvf
viru
recov
revers
genet
although
delet
exogen
sequenc
result
express
truncat
hmpvf
protein
amino
acid
length
retain
part
compris
signal
peptid
fusion
peptid
heptad
repeat
fragment
part
lack
heptad
repeat
b
tm
ct
domain
although
truncat
protein
immunogen
confer
protect
wt
immun
hamster
studi
show
vector
hmpv
antigen
sev
promis
strategi
solubl
form
hmpvf
protein
remain
immunogen
exampl
chimer
sev
shown
tabl
newcastl
diseas
viru
avian
paramyxoviru
serotyp
viru
import
poultri
pathogen
recent
drew
lot
attent
potenti
use
oncolyt
agent
vaccin
vector
although
recogn
avian
pathogen
experiment
proven
infect
sever
mammal
speci
includ
mice
hamster
guinea
pig
rabbit
ferret
calv
pig
nonhuman
primat
natur
ndv
infect
rare
human
case
infect
document
bird
handler
expos
viru
humantohuman
transmiss
ever
observ
variou
ndv
strain
classifi
low
virul
lentogen
mildli
virul
mesogen
highli
virul
velogen
concern
high
contagi
ndv
potenti
detriment
impact
poultri
industri
lentogen
strain
ndv
classifi
biosafeti
level
pathogen
mesogen
velogen
strain
pathogen
lentogen
strain
name
lasota
use
naturallyattenu
vaccin
protect
poultri
although
mesogen
ndv
strain
frequent
use
vaccin
vector
mesogen
strain
beaudett
c
bc
test
vaccin
vector
protein
nonhuman
primat
welltoler
immunogen
compar
lasota
strain
similarli
sev
ndv
safe
human
due
natur
host
rang
restrict
presenc
preexist
immun
highli
immunogen
induc
potent
ifn
type
respons
genom
approxim
kb
length
viru
adher
rule
six
effici
replic
viru
accommod
exogen
kb
length
effect
express
three
addit
protein
exogen
place
gene
junction
two
gene
viru
yet
posit
found
optim
ndv
vector
one
least
optim
ndv
use
vector
antigen
rsv
ampv
hiv
influenza
viru
sarscoronaviru
nipah
viru
ebola
viru
exampl
ndv
vector
pneumovir
antigen
report
tabl
although
ndv
yet
use
vector
hmpv
antigen
found
effici
backbon
surfac
protein
ampvc
lasota
ndv
strain
use
vector
g
protein
ampvc
test
bival
vaccin
ndv
ampvc
turkey
viru
confer
partial
protect
vaccin
bird
indic
ampvcg
protein
alon
suffici
induc
protect
immun
immunogen
construct
strongli
improv
ampvcf
g
protein
express
togeth
genom
posit
ndv
genom
similarli
hmpv
f
protein
ampvc
indispens
induc
potent
immun
respons
vaccin
host
vesicular
stomat
viru
pathogen
hors
livestock
belong
rhabdovirida
famili
rhabdovirida
paramyxovirida
belong
order
negativestrand
virus
mononegaviral
genom
vsv
singlestrand
nonseg
rna
neg
polar
approxim
kb
length
due
simplic
genom
use
model
studi
transcript
replic
nonseg
negativestrand
virus
nnsv
figur
vsv
share
advantag
viral
vector
paramyxovirus
although
superior
growth
vitro
provid
good
level
protein
express
chloramphenicol
acetyltransferas
protein
cat
express
posit
vsv
genom
constitut
protein
produc
rvsvinfect
cell
express
vsv
gene
follow
polar
gradient
observ
paramyxovirus
proxim
insert
posit
influenc
n
p
protein
ratio
detriment
viru
replic
n
p
ratio
shown
optim
viral
replic
wherea
ratio
valu
associ
decreas
replic
capac
viru
vsv
vector
two
potenti
drawback
name
neurotox
mediat
g
protein
induct
potent
vsvneutral
antibodi
respons
specif
g
protein
even
upon
singl
immun
make
boost
heterolog
vaccin
imposs
limit
futur
use
vsvbase
vaccin
vaccin
patient
neurotrop
result
signific
viral
replic
brain
mortal
mice
infect
vsv
rais
seriou
concern
use
viru
vaccin
vector
although
vsv
human
pathogen
human
infect
occur
result
contact
infect
anim
one
case
enceph
caus
vsv
infect
report
boy
panama
signific
morbid
vsvinfect
cattl
vsv
includ
list
potenti
harm
agent
unit
state
depart
agricultur
circumv
problem
gmediat
vsv
neurotox
attenu
vsv
g
protein
exchang
gp
protein
lymphocyt
choriomening
viru
lcmv
call
rvsvgp
design
chimer
viru
use
express
rsvf
protein
genom
posit
three
variant
nativ
codonoptim
codonoptim
tmct
domain
exchang
effici
express
nativ
rsvf
rsvg
protein
genom
posit
respect
also
document
rvsv
virus
test
vivo
construct
also
test
context
vsv
backbon
attenu
result
g
protein
delet
studi
show
backbon
attenu
less
immunogen
rvsv
combin
rsvg
antigen
effici
immun
nonpropag
recombin
vsv
bear
delet
membraneproxim
domain
g
protein
vsvgstem
use
vector
rsvf
g
protein
test
vivo
intranas
intramuscular
vaccin
vsv
also
use
express
hmpvf
protein
studi
aim
design
enzymelink
immunosorb
assay
elisa
specif
hmpv
studi
show
possibl
effici
express
hmpvf
protein
genom
posit
vsv
vector
exampl
vsvbase
chimer
vaccin
describ
tabl
chimer
vaccin
hmpv
advanc
clinic
trial
far
recombin
hmpv
viru
render
lessinfecti
result
replac
p
orf
counterpart
closelyrel
ampvc
strategi
attenu
base
restrict
replic
vivo
base
host
incompat
viral
compon
first
studi
hmpv
chimera
either
n
rhmpvna
p
rhmpvpa
gene
exchang
ampvc
counterpart
test
vaccin
hamster
agm
tabl
n
p
gene
ampvc
share
nucleotid
sequenc
ident
hmpv
counterpart
suggest
good
integr
heterolog
protein
hmpv
particl
rhmpvna
rhmpvpa
virus
replic
effici
vitro
compar
parent
hmpv
strain
test
vivo
hamster
replic
chimer
virus
decreas
rhmpvna
slightli
attenu
rhmpvpa
chimera
equal
immunogen
protect
vaccin
anim
wt
hmpv
infect
test
agm
rhmpvpa
attenu
rhmpvna
almost
equal
immunogen
chimera
confer
protect
wt
hmpv
studi
identifi
attenu
hmpvpa
chimera
promis
vaccin
candid
develop
rhmpvpa
viru
recent
test
vaccin
phase
clinic
trial
sequenti
adult
hmpvseroposit
hmpvseroneg
children
trial
found
rhmpvpa
viru
appropri
restrict
adult
seroposit
children
yet
insuffici
infecti
immunogen
hmpvseroneg
children
thu
leav
candid
antihmpv
vaccin
clinic
trial
describ
mani
studi
perform
viral
vector
mainli
paramyxovirus
express
pneumovir
protein
although
major
studi
focus
develop
antirsv
vaccin
result
indic
potenti
success
vaccin
candid
hmpv
efficaci
chimer
vaccin
hmpv
potenti
improv
mani
way
immunogen
hmpvf
protein
could
increas
codon
optim
human
express
modif
base
degeneraci
genet
code
make
possibl
optim
sequenc
order
improv
express
specif
express
system
exampl
human
cell
codon
optim
along
amino
acid
substitut
render
rsvf
amino
acid
sequenc
ident
earli
passag
origin
isol
heksubstitut
improv
immunogen
rsvf
protein
express
protect
wt
rsv
infect
codon
optim
alon
confer
increas
rsvf
express
heksubstitut
alon
confer
increas
although
exogen
protein
usual
wellexpress
surfac
cell
infect
chimer
virus
effici
incorpor
foreign
protein
viral
particl
remain
challeng
achiev
tmct
domain
swap
insert
vector
demonstr
viru
swap
either
ct
domain
tmct
domain
increas
packag
effici
reach
level
rsvf
packag
wt
rsv
virion
rsvf
tmct
insert
influenc
incorpor
vector
hn
protein
decreas
packag
f
protein
tmct
modif
influenc
viral
replic
vitro
result
increas
attenu
hamster
rhesu
macaqu
respect
similar
packag
improv
restrict
hamster
observ
bear
rsvf
tmct
gene
posit
interestingli
neither
ct
tmct
domain
exchang
improv
packag
effici
rsvf
vsvgp
particl
yet
tmct
modif
necessari
effici
express
surfac
protein
virus
exampl
prove
exchang
tmct
domain
could
attract
strategi
increas
incorpor
hmpv
antigen
vector
particl
yet
modif
caus
addit
attenu
effect
chimer
viru
combin
vector
antigen
requir
individu
design
demonstr
immun
express
rsvf
g
effici
simultan
immun
two
singleinsert
chimera
bear
either
rsvf
g
suppos
effect
due
interact
two
surfac
glycoprotein
close
associ
one
anoth
express
simultan
within
infect
cell
consid
structur
similar
rsv
hmpv
might
presum
simultan
express
hmpvf
g
protein
could
benefici
effect
efficaci
vaccin
also
demonstr
ampvc
howev
studi
perform
viruslik
particl
vlp
express
hmpvf
alon
along
g
protein
show
coincorpor
hmpvg
protein
vlp
improv
immunogen
confer
f
protein
therefor
like
coexpress
hmpvf
g
could
improv
vaccin
immunogen
improv
strategi
consid
anoth
possibl
strategi
improv
design
antihmpv
vaccin
could
express
one
copi
hmpv
antigen
hmpv
viru
express
two
addit
copi
f
gene
one
addit
copi
g
gene
genom
posit
describ
express
f
g
protein
mrna
recombin
hmpv
increas
respect
compar
wt
hmpv
vitro
replic
recombin
viru
approxim
reduc
compar
wt
hmpv
rel
small
reduct
consid
fact
genom
length
viru
increas
studi
show
ad
addit
copi
orf
hmpvf
orand
g
could
potenti
increas
express
antigen
also
backbon
vector
hmpv
rsv
import
pediatr
pathogen
despit
mani
year
research
vaccin
either
hmpv
rsv
current
avail
underlin
need
novel
solut
vaccin
design
optim
exist
strategi
gener
recombin
chimer
vaccin
protect
one
pathogen
advantag
practic
solut
elabor
promis
vaccin
candid
mani
studi
perform
vaccin
contain
antigen
rsv
express
heterolog
viru
mainli
f
protein
bival
vaccin
advanc
clinic
trial
although
possibl
gener
chimer
vaccin
hmpv
lessexplor
rsv
numer
similar
two
virus
serv
guid
design
antihmpv
vaccin
antigen
hmpv
rsv
success
express
variou
viral
vector
belong
paramyxovirida
famili
notwithstand
paramyxovirus
readili
express
exogen
protein
ad
gene
genom
mani
differ
factor
condit
viabil
chimer
viru
efficaci
exogen
express
immunogen
vaccin
candid
choic
vector
viru
need
taken
consider
variou
aspect
name
posit
exogen
vector
genom
size
type
insert
possibl
integr
foreign
protein
vector
particl
thoroughli
consid
numer
studi
engin
chimer
virus
indic
combin
must
care
design
individu
verifi
recombin
vaccin
candid
either
hmpv
rsv
design
date
indic
use
anoth
viru
express
hmpv
antigen
vice
versa
make
possibl
overcom
major
hurdl
hmpv
vaccin
develop
obtain
good
balanc
immunogen
attenu
live
recombin
vaccin
